title: Update on therapeutic options for multiple sclerosis.
abstract: Multiple sclerosis (MS) is one of the most common neurologic disorders that affects young people. The disorder has long been associated with clinical relapses and a disabling course. However, there has been a rapid expansion in the available treatment options for MS, and new insights into existing therapies, as decades of research has begun to produce tangible treatment results leading to newly approved an emerging therapies.
authors.affiliation: Loyola University Medical Center, Building 105, Room 2700, 2160 South First Avenue, Maywood, IL 60153, USA. mmccoyd@lumc.edu
authors.forename: Matthew
authors.initials: M
authors.lastname: McCoyd
mesh_terms: D002755:Choice Behavior; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000503:physiopathology / Q000628:therapy*
chemical_list: D007155:Immunologic Factors
keywords: Alemtuzumab (Lemtrada); BG-12 (Tecfidera); Fingolimod (Gilenya); McDonald criteria; Natalizumab (Tysabri); Teriflunomide (Aubagio); Vitamin D